Shizuoka, Japan

Masashi Nakakura

USPTO Granted Patents = 3 

Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 135(Granted Patents)


Location History:

  • Shizuoka-ken, JP (1997)
  • Shizuoka, JP (1997 - 1999)

Company Filing History:


Years Active: 1997-1999

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Masashi Nakakura: A Pioneer in Stabilization Methods

Introduction: Masashi Nakakura, an accomplished inventor based in Shizuoka, Japan, has significantly contributed to the field of pharmaceutical innovations. With a total of three patents to his name, Nakakura's work revolves around stabilizing complex compounds, showcasing his expertise and dedication to advancing medical science.

Latest Patents: Among his notable contributions, Masashi Nakakura's latest patents include "Method for Stabilizing Compound DX-52-1 and Lyophilized Composition" and "Method for Stabilizing Duocarmycin Derivatives." These patents reflect his innovative approach to ensuring the stability of important pharmaceutical compounds, which is essential for their effective use in medical treatments.

Career Highlights: Nakakura has worked with prestigious companies such as Kyowa Hakko Kogyo Co., Ltd. and Alcon Laboratories, Inc. His experience in these organizations has provided him with a solid foundation in research and development, driving his passion for discovering new methods and techniques in drug stabilization.

Collaborations: Throughout his career, Nakakura has collaborated with talented individuals including Eiji Hayakawa and Tokuyuki Kuroda. These partnerships have undoubtedly enriched his research endeavors and contributed to the successful development of his patented methods.

Conclusion: Masashi Nakakura stands out as a key figure in the field of pharmaceutical inventions. His innovative patents demonstrate his commitment to advancing drug stability techniques, which are vital for the health and wellbeing of patients. As he continues his work, the impact of his contributions will undoubtedly resonate within the pharmaceutical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…